Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp (MDNAF) is a clinical-stage biopharmaceutical company advancing targeted cytokine therapies for cancer and immune disorders. This news hub provides investors and researchers with verified updates on the company’s therapeutic developments, strategic partnerships, and clinical progress.
Access real-time announcements about MDNAF’s innovative immunotherapy pipeline, including updates on superkine engineering, empowered cytokine platforms, and trial milestones. The repository consolidates essential documents such as earnings reports, regulatory filings, and scientific presentations, offering a comprehensive view of corporate and research activities.
Key content categories include clinical trial advancements, intellectual property updates, executive leadership changes, and collaborative research initiatives. All materials are sourced directly from company communications to ensure accuracy and compliance with disclosure standards.
Bookmark this page for streamlined access to Medicenna’s latest developments in precision immunotherapy. Check regularly for updates on novel therapeutic candidates designed to address unmet needs in oncology through selective cytokine modulation.
Medicenna Therapeutics announced that Dr. Fahar Merchant, its President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:00 AM ET. The presentation will provide an overview of the company's immuno-oncology developments, including its promising MDNA11 and MDNA55 assets, focused on cancer treatment. A live webcast will be accessible here. A replay will be available post-event on Medicenna's website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced promising preclinical data for MDNA19-MDNA413, a dual-specific cytokine developed from their BiSKITs™ platform, presented at the AACR Annual Meeting. This innovative therapy selectively activates anti-cancer immune cells while inhibiting pro-tumoral macrophage polarization. Key findings highlighted a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, and effective suppression of IL-13 induced M2a macrophage polarization. Medicenna plans to advance its development and regulatory submissions for MDNA11, another promising superkine therapy.
FAQ
What is the current stock price of Medicenna Therapeutics (MDNAF)?
What is the market cap of Medicenna Therapeutics (MDNAF)?
